Biovail Sues Impax Over Wellbutrin XL Patent

Law360, New York (March 9, 2005, 12:00 AM EST) -- A subsidiary of Canadian drug maker Biovail Corp. has filed a lawsuit against Impax Laboratories Inc. over Impax's plans to launch a generic version of Biovail's antidepressant drug Wellbutrin XL.

The lawsuit, filed in the U.S. District Court for the Eastern District of Pennsylvania in Philadelphia, alleges patent infringement related to Impax’s filing for a generic version of the antidepressant with the U.S. Food and Drug Administration.

Impax has submitted its filing under Paragraph IV of the Hatch-Waxman Amendments, stating that it believes its generic versions...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.